2d
Strengthen Total AAV Potency Assurance with NGS Sequence Analysis, Upcoming Webinar Hosted by Xtalks
Demonstration of therapeutic potency is critical for successful development and commercialization of viral-vector based ...
Discover how automated purification workflows can increase throughput, improve reproducibility, and simplify protein, ...
Adeno-associated virus (AAV)-based viral vectors used in human gene therapy can trigger innate immune pathways, leading to the initiation of adaptive immune responses. A new review article published ...
An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent cells and leading to syndromic hearing loss. In a new experimental study, ...
Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX ...
AI-assisted adeno-associated virus (AAV) capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies. That’s the view of Fangzhi Tan, PhD, ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...
Tech Times on MSN
Skylark Bio doses first child with GJB2 gene therapy, no treatment has ever existed
GJB2 gene therapy enters human testing for the first time as Skylark Bio doses the first child in the SONIX Phase 1/2 trial, ...
Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results